Aarey Drugs & Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

3.77×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.81×	1.81×	2.20×	0.58×	1.61×
1.53×	1.53×	1.73×	0.38×	1.44×
1.4	1.4	1.5	1.6	0.7
118	118	116	−70.1	102

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AAREYDRUGS₹110.84

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersNECLIFE NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹315 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	3.77
Current Ratio	1.61	0.58	2.20	1.81	1.81
Quick Ratio	1.44	0.38	1.73	1.53	1.53
Cash, Equiv & ST Investments	0.7	1.6	1.5	1.4	1.4
Working Capital	102.5	-70.1	116.4	117.9	117.9

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.